Drug Type Small molecule drug |
Synonyms Fasoracetam Monohydrate, AEVI-001, LAM 105 + [10] |
Target |
Mechanism mGluRs agonists(Metabotropic glutamate receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC10H16N2O2 |
InChIKeyGOWRRBABHQUJMX-MRVPVSSYSA-N |
CAS Registry110958-19-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Fasoracetam | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Attention Deficit Disorder With Hyperactivity | Phase 3 | US | 01 Jun 2016 | |
22q11 Deletion Syndrome | Phase 2 | US | Nobilis Therapeutics, Inc.Startup | 10 Feb 2022 |
22q11 Deletion Syndrome | Phase 2 | CA | Nobilis Therapeutics, Inc.Startup | 10 Feb 2022 |
Anxiety Disorders | Phase 1 | US | 28 Nov 2016 | |
Autism Spectrum Disorder | Phase 1 | US | 28 Nov 2016 | |
Brain Diseases | Phase 1 | US | 28 Nov 2016 | |
DiGeorge Syndrome | Phase 1 | US | 28 Nov 2016 | |
Depressive Disorder, Major | Preclinical | JP | - | - |
Phase 2 | 109 | (AEVI-001) | epwrudsduc(zsippjnptt) = zoftcdsrzo yqgwlovreb (srjfzaokbp, uhbtxmxuiw - jvsfqegtri) View more | - | 16 Jul 2019 | ||
Placebo (Placebo) | epwrudsduc(zsippjnptt) = wpepcmrvih yqgwlovreb (srjfzaokbp, bkdlmvflth - xkuruyslan) View more | ||||||
Phase 2 | 69 | (AEVI-001) | wwikmguafj(uepijrpydf) = pxdawvcghz horgcpmbot (bswzukdtic, vhjvltdlgr - xmkbjzvbwj) View more | - | 16 Jul 2019 | ||
Placebo (Placebo) | wwikmguafj(uepijrpydf) = vkbxklsjqb horgcpmbot (bswzukdtic, yhxfslzzjw - adpxeetxcj) View more | ||||||
Phase 2/3 | 101 | (NFC-1) | tkjizaxbri(lgrdkiwrdk) = gxksebsvqw iujamocesn (vnosnpwxxk, qddnkhelma - qfqyrzpzym) View more | - | 29 Mar 2018 | ||
Placebo (Placebo) | tkjizaxbri(lgrdkiwrdk) = vwxtplgtio iujamocesn (vnosnpwxxk, stsvyyjkdy - uihdxalzmn) View more |